Older patients hospitalized for heart failure with reduced ejection fraction continue to experience a high clinical and economic burden even after receiving quadruple medical therapy.
Heart failure management includes the four pillars (quad therapy) in HFrEF and HFpEF, plus advances in heart transplantation ...
A newly developed fine-grained framework assesses transthoracic echocardiography image quality, revealing significant ...
Oral semaglutide lowers heart failure events in people with type 2 diabetes and existing heart failure without increasing ...
By slicing and dicing the data, the study confirms MITRA-FR as an outlier and emphasizes the need for careful patient selection.
Novartis (SWX:NOVN) has recorded its 29th consecutive annual dividend increase, extending a nearly three decade payout track ...
Germany: In 2025, several high-impact studies significantly advanced the understanding and management of heart failure (HF), ...
The data supporting safety and effectiveness for the Helix Pre-Submission is from fifteen well-controlled clinical trials of cell and gene therapy delivery to the heart using Helix, where patients ...
MercyOne uses new technology for heart failure treatment in Iowa ...
UC labs are developing new treatments that don’t just prevent damage from getting worse, but — for the first time in medical ...
Stockhead on MSN
Biocurious: Without a hint of hyperbole, ASX stem-cell developers lead the way on world-first therapies
Following Mesoblast's breakthrough FDA approval for its stem-cell therapy, activity in the sector has burgeoned and investors should stay tuned ... Read More The post Biocurious: Without a hint of ...
In patients with type 2 diabetes and heart failure, those assigned oral semaglutide had reduced risk for heart failure events ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results